Companies Dominating the Potassium-Sparing Diuretics Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck Sharp & Dohme Corp.
- Accord Healthcare
- Amneal Pharmaceuticals LLC
- Centaur Pharmaceuticals Pvt. Ltd.
- Validus Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- CMP Pharma
- Boehringer Ingelheim GmbH
- Bayer AG
Browse Key Market Insights with Data Illustration:
In the News
-
A new FDA approval for Merck & Co., Inc., VERQUVO® (vericiguat) has been announced. heart failure (HF) hospitalization risk reduction with VERQUVO in adults with symptomatic chronic heart failure and a low ejection fraction (45%) after heart failure hospitalization or need for intravenous (IV) diuretics in adults.
-
In a joint announcement today, Boehringer Ingelheim GmbH and Eli Lilly and Company announced that Jadix® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration for the reduction of cardiovascular death and hospitalization associated with heart failure in adults with heart failure with reduced ejection fractions (HFrEF).
